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ABSTRACT
Interpretation of thyroid function test (TFT) is often straightforward but in certain scenarios, discordance between the 
clinical impression and the laboratory results exists. A 50-year-old woman with a ten years history of hypothyroidism 
on levothyroxine presented with a recent notable change in TFT [elevated free thyroxine (FT4) and thyroid-stimulat-
ing hormone (TSH)], in an otherwise clinically euthyroid and previously stable TFT, leading to levothyroxine being 
withheld. This case report highlights the possibility of assay interference as a cause of discordant TFT. It also draws 
the importance of close collaboration between clinicians and the laboratory to avoid unnecessary investigations and 
inappropriate management of such a case.
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INTRODUCTION
Thyroid stimulating hormone (TSH) and free thyroxine 
(FT4) tests are routinely requested for evaluation of 
thyroid function. Often, these thyroid function tests (TFTs) 
are easily interpreted in confirming the clinical diagnosis 
of hypothyroidism or hyperthyroidism. Occasionally, 
clinical and biochemical thyroid function mismatch, 
termed discordant TFT occurs, the pattern of which may 
point towards its possible causes, such as analytical 
interference in FT4 assay, as illustrated in this case. 
Failure to recognise such cause can lead to unnecessary 
investigations and inappropriate management (1).
CASE REPORT
A 50-year-old woman with known hypothyroidism 
on levothyroxine 50 micrograms daily for the past ten 
years presented with raised FT4 (27.5 pmol/L) and TSH 
(33.1 mIU/L) during a routine follow up (June 2016) 
at a primary-care centre (Table I).  She was clinically 
euthyroid and her TFT results six months prior were 
normal. Three months later, a similar TFT pattern was 
obtained, resulting in the patient’s levothyroxine being 
discontinued. Subsequently, the patient developed 
hypothyroidism symptoms mainly weight gain (6 kg 
within a month) and fatigue which corresponded to a 
TSH  level of >150 mIU/L (November 2016) (Table I). 
Table I: TFT results during follow up at the primary-care physician
Modular E170 (Roche 
Diagnostics)
ADVIA Centaur XPT 
(Siemens Healthcare)
Date/ Tests FT4
(12.0 - 22.0 
pmol/L)
TSH
(0.27-4.20 
mIU/L)
FT4
(11.5-22.7 
pmol/L)
TSH
(0.55-4.78 
mIU/L)
December 2015 18.13 1.09 - -
June 2016 - - 27.5 33.10
September 2016 - - 33.1 47.52
November 2016 - - 17.0 > 150
She was restarted on levothyroxine 50 micrograms 
daily following a referral to the endocrinologist of 
Hospital Melaka. At this time, a history of occasional 
noncompliance was also elicited and she was advised 
to improve. Two months later (January 2017) (Table II) 
her FT4 remained elevated (27.6 pmol/L) and her TSH 
had normalised (64.05 mIU/L) while she was clinically 
euthyroid. Levothyroxine was decreased from once daily 
for 7 days to 5 days per week. All other biochemical 
investigations (renal profile, fasting lipid profile, liver 
function test, and full blood count) were normal. Her 
clinical and biochemical status remained status quo two 
months later (April 2017).
At this point of time, analytical interference in the 
TFT assays was considered as a possible cause of the 
discordant TFT. Biochemical tests from the health clinic 
at which patient was on follow-up were sent to Pathology 
Laboratory in Hospital Melaka. It was realised that the 
laboratory had changed its platform for TFT assays 
from Modular E170 (Roche Diagnostics) to ADVIA 
Centaur XPT (Siemens Healthcare) in the first quarter of 
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of TSH following adequate levothyroxine dosages. RTH 
was also unlikely as affected patient would otherwise 
be clinically euthyroid. Hence investigations such as 
pituitary MRI scanning and TRH test were not performed. 
Discordant TFT  (increased TSH/increased FT4) may be 
caused by continuous disequilibrium between FT4 and 
TSH (2). In this patient, the occasional noncompliance 
was, reflected by her elevated TSH levels from June-
September 2016, which revealed her true clinical 
status despite being asymptomatic. Furthermore, it 
was misled by increased FT4 levels. Discontinuation 
of levothyroxine eventually unmasked her true clinical 
state of hypothyroidism in November 2016, which was 
biochemically evident by a significantly elevated TSH. 
Although the FT4 had decreased to within the reference 
interval, it was actually falsely high. A sudden alteration 
in the pattern of the patient’s TFT results following the 
change of the laboratory’s analyser should have hinted 
the possibility of assay interference, given the previously 
stable TFTs. 
FT4 is often measured using a competitive immunoassay 
method (1). Known FT4 immunoassay interference 
includes biotin, heterophile antibodies, human anti-
animal antibodies (HAAA) and thyroid hormone 
autoantibodies (THAAb) (1).  These interferents may alter 
the FT4 measurements depending on the immunoassay 
format and types of reagent antibodies, immobilising and 
detection systems used (1). In this case, the interference 
in the ADVIA Centaur XPT (Siemens Healthcare) FT4 
assay had resulted in falsely higher values whilst the 
other FT4 assays were unaffected. Although all three 
are competitive immunoassays, they differ in several 
aspects (Table III). The ADVIA Centaur XPT (Siemens 
Healthcare) FT4 is a one-step assay, in which the 
endogenous FT4 in the patient’s serum competes 
with the assay’s labelled T4 analogue for binding to a 
limited amount of biotinylated polyclonal rabbit anti-T4 
antibody immobilised to a solid surface. Any unbound 
fraction is removed during a washing step and the 
Table II: TFT results during follow up at Endocrine Clinic Hospital 
Melaka
Date/ 
Tests
ADVIA Centaur XPT 
(Siemens Healthcare) 
(Hospital Melaka)
Cobas e601 (Roche 
Diagnostics) (HKL)
UniCel Dxl 800 
(Beckman Coulter, 
Inc) (HPJ)
FT4
(11.5-
22.7 
pmol/L)
TSH
(0.55-
4.78 
mIU/L)
FT4
(12.0-
22.0 
pmol/L)
TSH
(0.27-
4.20 
mIU/L )
FT4
(11.5-
22.7 
pmol/L)
TSH
(0.55-
4.78 
mIU/L)
Jan-
uary 
2017
27.6 64.05 - - - -
April 
2017
29.6 54.68 11.5 63.09 8.6 52.53
May 
2017
25.3 85.50 - - - -
July 
2017
39.3 0.11 26.4 0.17 - -
Sep-
tem-
ber
2017
27.7 0.32 18.8 0.40 - -
De-
cem-
ber 
2017
32.3 0.31 22.5 0.40 - -
April 
2018
34.1 0.24 23.4 0.25 - -
2016.  As part of the investigation, the patient’s blood 
samples were sent to two different centres [Hospital 
Putrajaya (HPJ) and Hospital Kuala Lumpur (HKL)], 
which used UniCel Dxl 800 (Beckman Coulter) and 
Cobas e601 (Roche Diagnostics) platforms, respectively. 
In contrast to the results obtained on ADVIA Centaur 
XPT (Siemens Healthcare), the TFT results from both 
the centres showed low FT4 with raised TSH (Table 
II) consistent with the patient’s initial diagnosis. Her 
levothyroxine dose was increased to 100 micrograms 
daily. A diagnosis of hypothyroidism on treatment 
with discordant TFT secondary to FT4 immunoassay 
interference was made.  The patient continued to be 
on follow-up at the endocrine clinic whereby her 
levothyroxine dosages were adjusted clinically, guided 
by her Cobas e601 (Roche Diagnostics) TFT results. As 
she remained asymptomatic, further investigations such 
as imaging and other specific laboratory tests to rule out 
other causes of discordant TFT were not performed.
DISCUSSION
The causes of hyperthyroxinaemia with raised TSH, as 
seen in this patient include a) assay interference to FT4 
or TSH assays, b) non-thyroidal illness (NTI), c) TSH 
secreting pituitary adenoma (TSHoma), d) resistance 
to thyroid hormone (RTH) and e) medications such 
as amiodarone and thyroxine replacement therapy 
(including poor compliance) (2). Having no history 
of acute or chronic illnesses as supported by normal 
routine blood investigations, and prescription of  other 
medications, exclude NTI and medication as causes 
of the discordant TFT. TSHoma which would result in 
hyperthyroidism, was unlikely given her longstanding 
history of hypothyroidism and the drastic normalisation 
Table III: Principles of FT4 immunoassays
Character-
istics 
ADVIA Centaur 
XPT (Siemens 
Healthcare)
Cobas e601 
(Roche Diagnos-
tics) 
UniCel Dxl 800 
(Beckman Coulter, 
Inc)
Type One-step com-
petitive
One-step com-
petitive
Two-step compet-
itive
Steps One incubation 
and one wash
Two incuba-
tions, one-wash 
Two incubations, 
two-wash
Antibody Polyclonal rabbit 
anti-T4 antibody, 
coupled to biotin
 Polyclonal 
sheep anti–T4 
antibody, 
labelled with 
ruthenium 
complex
Monoclonal mouse 
anti-T4 antibody, 
coupled to biotin
T4 analogue T4 labelled with 
acridinium ester
T4 coupled with 
biotin
T4 labelled 
Solid phase avidin-coated 
paramagnetic 
microparticles 
streptavi-
din-coated 
paramagnetic 
microparticles
streptavidin-coat-
ed paramagnetic 
microparticles
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signal generated from the bound labelled T4 analogue 
is measured. The Cobas e601 (Roche Diagnostics) FT4 
assay is also a one-step immunoassay but is performed 
in two sequential incubations with one washing step 
at the end. In contrast, the UniCel Dxl 800 (Beckman 
Coulter) FT4 is a two-step assay with washing steps in 
between and at the end. 
The three immunoassay systems exploit the biotin-
streptavidin interaction leaving them potentially 
susceptible to biotin interference with increasingly 
reported cases over recent years (3,4). The magnitude 
of interference, however, is dependent on the extent of 
excess biotin in the sample and the interference threshold 
of the assay (3,4).  The excess biotin will bind to the 
streptavidin-solid surface and prevents immobilisation of 
biotinylated antibody leading to falsely increased result 
in competitive immunoassays.  In this patient, biotin was 
an improbable cause for the interference as the patient 
had no history of biotin intake. In addition, ADVIA 
Centaur XPT (Siemens Healthcare) uses preformed 
biotin-avidin solid phase, making it insensitive to biotin 
interference, compared to non-preformed system (5). 
Patient’s samples may contain heterophilic or human 
anti-animal antibodies (HAAA) that are capable of 
binding to the animal antibodies used in the immunoassay 
system. By definition, HAAA are high-affinity antibodies 
that developed towards specific animal epitopes (e.g. 
mice and rabbits) while heterophilic antibodies are 
weak antibodies formed in response to poorly defined 
antigens (4). In patients with no history of receiving 
animal monoclonal immunoglobulin (MAb) injections 
such as in this patient, the term heterophilic antibody 
is preferred. However, this was unlikely in this patient 
as such interference more commonly affects non-
competitive assay such as TSH, compared to competitive 
assay (4). 
THAAb directed against T4 is a possible cause of FT4 
assay interference in this patient. THAAb is present in 
<2% of the general population but in as high as 40% 
in those with autoimmune thyroid disease (AITD) (4). 
Between 80-100% of samples with THAAb are positive 
for anti-thyroid peroxidase or anti-thyroglobulin 
antibodies although these were never measured during 
this patient’s 10-year history of hypothyroidism (1,4). 
THAAb tends to affect one-step assays as it forms a 
complex with the labelled T4 analogue preventing the 
complex from binding to the solid phase and hence 
leading to a falsely elevated FT4. Two-step assay, as 
utilised by UniCel Dxl 800 (Beckman Coulter), on the 
other hand, is considered less sensitive towards these 
autoantibodies since the THAAb are removed during 
the intermediate washing step, before the introduction 
of the labelled T4 analogue (4). Similarly, staggered 
incubation in one-step assay on Cobas e601 (Roche 
Diagnostics) limits the duration of contact between 
THAAb and the T4 analogue, rendering it less sensitive 
to this interferent (4), as shown in Table II.  As AITD is 
one of the commonest cause of hypothyroidism, THAAb 
seems to be the most likely interferent in FT4 assay in 
this case. 
A hyperthyroxinaemia with raised TSH in a patient with 
a longstanding history of hypothyroidism was highly 
suspicious of assay interference. As such, retesting 
with other immunoassay platforms was a good initial 
approach (1), as demonstrated in this case. Other 
investigations for suspected interference include a 
demonstration of nonlinearity with sample dilution, 
removal of interfering antibodies using a nonimmune 
serum or heterophilic blocking tubes, or precipitation 
with polyethylene glycol (2). These tests were, however, 
not performed due to non-availability and limited 
resources. Ideally, one should elicit the underlying 
cause of such assay interference and findings should be 
documented to avoid future mismanagement. 
CONCLUSION
Immunoassay is prone to interference (4). Both the 
clinicians and laboratorians need to be mindful of such 
probability in the differential diagnosis of discordant TFT. 
In any case, not only correlation with clinical history is 
mandated, efforts should also be given in eliciting the 
underlying cause of assay interference.  
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